Research
Hormonal
GLP-1 agonists may provide additional benefits beyond weight loss and diabetes management.
Providers should explore the broader implications of GLP-1 agonists for patients with various conditions.
GoodQualifiesmedium confidence
there also may be other benefits seen with GLP-1 agonist usage in specific populations such as cardiovascular disease, neurodegenerative diseases, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.
Why this rating
The claim is based on supporting trial data but is less definitive.
Source
GLP-1 Agonists for Weight Loss and Beyond
Connor Quinter et al. · Transformative Medicine · 2024
DOI 10.54299/tmed/curq6915
reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →